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Abstract
Inactivation of p53 contributes signiﬁcantly to the dismal prognosis of breast tumors, most notably triple-negative breast
cancers (TNBCs). How the relief from p53 tumor suppressive functions results in tumor cell aggressive behavior is only
partially elucidated. In an attempt to shed light on the implication of microRNAs in this context, we discovered a new
signaling axis involving p53, miR-30a and ZEB2. By an in silico approach we identiﬁed miR-30a as a putative p53 target
and observed that in breast tumors reduced miR-30a expression correlated with p53 inactivation, lymph node positivity and
poor prognosis. We demonstrate that p53 binds the MIR30A promoter and induces the transcription of both miRNA strands
5p and 3p. Both miR-30a-5p and -3p showed the capacity of targeting ZEB2, a transcription factor involved in
epithelial–mesenchymal transition (EMT), tumor cell migration and drug resistance. Intriguingly, we found that p53 does
restrain ZEB2 expression via miR-30a. Finally, we provide evidence that the new p53/miR-30a/ZEB2 axis controls tumor
cell invasion and distal spreading and impinges upon miR-200c expression. Overall, this study highlights the existence of a
novel axis linking p53 to EMT via miR-30a, and adds support to the notion that miRNAs represent key elements of the
complex network whereby p53 inactivation affects TNBC clinical behavior.
Introduction
Breast cancer (BC) is the most common cancer among
women. Despite signiﬁcant advances in early diagnosis and
treatment, metastatic spread still represents a major cause of
death for BC patients. BCs are typically classiﬁed into
hormone receptor positive (HR; estrogen receptor and/or
progesterone receptor), HER2/ERBB2/NEU-positive or
triple-negative tumors (TNBC, negative for hormonal and
HER2 receptors) according to their receptor status, as
assessed by immunohistochemistry. In 2000, Perou et al. [1]
suggested a molecular classiﬁcation of BC into four major
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subgroups based on the transcriptional proﬁle. These four
molecular BC subtypes overlap only in part with the con-
ventional receptor classiﬁcation: luminal A and luminal B,
including most of HR-positive tumors; HER2-positive
tumors; and basal-like BC, grossly corresponding to
TNBC [1]. Among the different BC subtypes, TNBC/basal-
like tumors feature a particularly aggressive behavior:
compared to the other BC subtypes, TNBC patients tend to
relapse earlier and have higher recurrence rates in the ﬁrst
years after diagnosis [2]. In fact, in the absence of an
approved target therapy for TNBC, radiotherapy and che-
motherapy still represent the mainstay of treatment [3].
Unfortunately, primary or secondary resistance often
occurs, which contributes to the dismal prognosis of these
tumors [3].
The inactivation of the tumor suppressor p53 is thought
to play a major role in the aggressiveness of TNBC by
promoting metastatic spreading, resistance to therapy and
relapse [4]. In TNBC/basal-like BC, TP53 alterations
involve over 80% of the tumors and are mostly represented
by disrupting mutations (gene deletions or insertions).
Instead, only 19% of HR-positive/luminal tumors present
TP53 alterations (12% of luminal A, 29% of luminal B) that
are primarily missense mutations [5]. These facts support
the notion that p53 contributes to TNBC/basal-like BC
mostly through loss of tumor suppressive functions, rather
than through gain of oncogenic activities (gain-of-function
p53 mutations).
Loss of function of p53 results in the abolition of p53-
mediated checkpoints and stress responses, and recent evi-
dence points to a role of microRNAs (miRNAs) in these
contexts [6–8]. miRNAs are small, non-coding RNAs that,
through base pairing with target messenger RNA (mRNA)
molecules, regulate gene expression by inducing either
mRNA degradation or inhibition of translation [9, 10]. p53
has been described to regulate the expression of a number of
miRNAs that mediate p53 control over several biological
processes including cell cycle, epithelial–mesenchymal
transition (EMT) and cell plasticity, survival and metabo-
lism [6,11–14]. On these grounds we sought to investigate
in deeper detail the contribution of miRNAs as mediators of
p53 tumor suppressive functions in the context of TNBC/
basal-like tumors.
Results
miR-30a is downregulated in TP53-inactivated TNBC
and correlates with poor outcome
To investigate the possible contribution of a p53/miRNA
pathway in the pathogenesis and aggressive behavior of BC,
we took advantage of the in silico predictor of p53-
responsive elements developed by Gowrisankar and Jegga
[15]. The algorithm identiﬁed 23 miRNAs as high con-
ﬁdence p53 targets (score ≥ 3). The interrogation of the
publicly available TCGA (The Cancer Genome Atlas) BC
dataset (at http://tcga-data.nci.nih.gov/tcga/ﬁndArchives.
htm [16]) highlighted 13/23 miRNAs as signiﬁcantly
modulated in TP53-mutated (including missense mutations,
deletions and insertions) compared to TP53 wild-type BC
(Table 1). Among these, miR-30a stood out as it was the
only miRNA to be signiﬁcantly downregulated in TP53-
mutated tumors. The presence of several putative p53-
responsive elements in the promoter region of miR-30a was
also conﬁrmed by the MatInspector tool [17]. This ﬁnding
was suggestive of a potential control of p53 over miR-30a
gene expression.
To address the actual existence of a p53/miR-30a inter-
play in the context of BC we further interrogated the TCGA
database for miR-30a expression. In the biogenesis of a
Table 1 Differentially expressed miRNAs predicted to be p53-
regulated in TP53-mutated and TP53 wild-type breast cancers
miRNA predicted to
be regulated by p53a
Transactivation
scorea
LOG2 fold
changeb
P-valuec
miR-146a 3 1.2 2.1E−07
let-7i 3 0.5 1.6E−06
miR-671 4 0.6 1.9E−06
miR-30a 3 -0.8 8.5E−06
miR-138-2 3 3.1 1.9E−04
miR-138-1 4 3.7 3.6E−04
miR-15b 3 0.8 4.8E−04
miR-615 3 0.8 5.6E−04
miR-9-2 3 2.4 2.0E−03
miR-196a-2 3 0.6 9.2E−03
miR-181a-1 3 0.3 1.0E−02
miR-191 4 0.4 1.3E−02
miR-328 4 0.3 3.4E−02
miR-490 3 2.1 9.4E−02
miR-194-1 3 0.2 1.1E−01
miR-302b 4 ND 2.3E−01
miR-34a 3 0.2 2.4E−01
miR-135a-2 3 –1.6 2.6E−01
miR-153-2 3 –0.3 3.9E−01
miR-1-1 3 –3.0 4.5E−01
miR-124-3 4 1.2 5.0E−01
miR-100 3 0.1 7.2E−01
miR-29b-2 3 0.0 8.3E−01
aTransactivation score as calculated by Gowrisankar and Jegga [15]
bData are reported as LOG2 fold change between TP53-mutated (82
cases) and wild-type (163 cases) breast cancers (TCGA series; strands
from the same miRNA were jointly analyzed)
cThe top 13 miRNAs were differentially expressed (p < 0.05) in TP53-
mutated vs wild-type breast cancers
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miRNA, the primary miRNA (pri-miRNA) transcribed from
the miRNA gene is ﬁrst processed into a precursor miRNA
(pre-miRNA) to then form a guide miRNA, which regulates
target mRNA expression [9]. The other strand, named
passenger strand, is usually degraded, but there are
examples in which both strands give rise to mature miRNAs
[9, 10]. Analysis of miR-30a expression revealed that this
was indeed the case for miR-30a. In fact, both miR-30a-5p
and miR-30a-3p were expressed in normal breast tissues,
and both were signiﬁcantly downregulated in BC (p < 0.01,
Fig. 1 miR-30a-5p and miR-30a-3p expression in breast cancers of the
TCGA series (a–c) and of the in-house series (d–f). TCGA series: a
the expression levels of miR-30a-5p and miR-30a-3p (expressed as
LOG2 RPM) are lower in breast tumors (T) compared to matched
normal breast tissues (N; 12 cases). b, c miR-30a-5p and miR-30a-3p
levels are lower in the 82 BCs carrying TP53 mutations (missense,
nonsense, frameshift; TP53 mut) compared to the 163 TP53 wild-type
tumors (TP53 WT) (b) and in TNBC (27 cases) compared to hormone
receptor-positive tumors (HR, 204 cases) (c). The p values were
calculated by Mann–Whitney rank sum test; *p < 0.05, **p < 0.01.
In-house series: d low levels of either miRNA strand are associated
with lymph node positivity. Data are reported as LOG2 of miRNA
relative levels; p values were calculated by two-tailed t-test; *p < 0.05,
**p < 0.01. e, f Kaplan–Meier analysis showing overall survival in the
TNBC patients classiﬁed according to miR-30a-5p (e) and miR-30a-3p
(f) median levels. Survival curves are truncated at 84 months. In (a–d)
lines within the boxes mark the median, boundaries represent the 25th
and the 75th percentiles and whiskers below and above the boxes
indicate the 5th and 95th percentiles
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Fig. 1a), with a high degree of reciprocal correlation (r=
0.80, p < 0.01). Interestingly, the expression of both miR-
30a strands was signiﬁcantly lower in TP53-inactivated
BCs compared to TP53 wild-type BCs, irrespective of the
type of mutation (Fig. 1b; Supplementary Figure S1a).
Moreover, miR-30a downregulation was more dramatic in
TNBC compared to HR-positive tumors (Fig. 1c). The
difference in miR-30a expression observed between TNBC
and HR-positive tumors was most likely attributable to p53,
as the statistical difference between the two subtypes was
lost when corrected for TP53 gene status (Supplementary
Figure S1b).
To investigate a possible role of miR-30a in the
aggressive behavior of TNBC, we then interrogated an in-
Table 2 Triple-negative breast cancers cases: distribution according to miR-30a (5p and 3p) expression, demographics and clinical pathological
features
miR-30a-5p miR-30a-3p
Total
(N=59)
Lowa
(N=29)
Higha
(N=30)
P-value Lowa
(N=29)
Higha
(N=30)
P-value
Median follow-up
(months)
63.2 61.0 65.4 0.87c 51.3 67.7 0.06c
Median age at
diagnosis (yrs)
51 49 52 0.50c 52 50 0.13c
No. (%) No. (%) No. (%) No. (%) No. (%)
Tumor sizeb
T1 28 (52.8) 12 (42.9) 16 (64.0) 0.09d 11 (39.3) 17 (68.0) 0.06d
T2 22 (41.5) 13 (46.4) 9 (36.0) 14 (50.0) 8 (32.0)
T3–T4 3 (5.7) 3 (10.7) 0 (0.0) 3 (10.7) 0 (0.0)
Lymph nodesb
N0 28 (47.5) 10 (35.7) 18 (75.0) 0.01d 9 (32.1) 19 (79.2) <0.001d
N+ 24 (40.7) 18 (64.3) 6 (25.0) 19 (67.9) 5 (20.8)
Metastasis
M0 54 (91.5) 28 (96.6) 26 (86.7) 0.35d 27 (93.1) 27 (90.0) 1.00d
M+ 5 (8.5) 1 (3.5) 4 (13.3) 2 (6.9) 4 (10.0)
TNM stage
I 19 (32.2) 8 (27.6) 11 (36.7) 0.80d 7 (24.1) 12 (40.0) 0.43d
II 25 (42.4) 13 (44.8) 12 (40.0) 13 (44.8) 12 (40.0)
III–IV 15 (25.4) 8 (27.6) 7 (23.3) 9 (31.0) 6 (20.0)
Tumor gradeb
G1–G2 3 (5.1) 1 (3.6) 2 (6.7) 1.00d 0 (0.0) 3 (10.4) 0.24d
G3 55 (93.2) 27 (96.4) 28 (93.3) 29 (100.0) 26 (89.7)
Radiation treatmentb
No 23 (45.1) 10 (38.5) 13 (52.0) 0.40d 11 (45.8) 12 (55.6) 1.00d
Yes 28 (54.9) 16 (61.5) 12 (48.0) 13 (54.2) 15 (44.4)
Pharmacological treatmentb
No 9 (16.1) 3 (11.1) 6 (20.7) 0.47d 4 (14.8) 5 (17.2) 1.00d
Yes 47 (83.9) 24 (88.9) 23 (79.3) 23 (85.2) 24 (82.8)
Drugsb
Anthracycline 21 (47.7) 14 (60.9) 7 (33.3) 0.23d 11 (52.4) 10 (43.5) 0.73d
Anthracycline/Taxanes 11 (25.0) 4 (17.4) 7 (33.3) 4 (19.0) 7 (30.4)
CMF 12 (27.3) 5 (21.7) 7 (33.3) 6 (28.6) 6 (26.1)
CMF cyclophosphamide, methotrexate and 5-ﬂuorouracil
aThe median value was used as cut-off
bThe sum does not add up to the total because of some missing values
cMann–Whitney–Wilcoxon test
dFisher’s exact test
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house cohort of 59 consecutive TNBCs with full clinical
history (Table 2): the expression of miR-30a, particularly
miR-30a-3p, inversely correlated with lymph node posi-
tivity (Fig. 1d), shorter disease-free (data not shown) and
overall survival (Fig. 1e, f). Taken together, these results
suggested a concerted action of p53 and miR-30a in the
control of TNBC clinical outcome.
miR-30a is a direct transcriptional target of p53
Based on the data accumulated, we sought to investigate in
detail the p53/miR-30a interplay. In keeping with the in
silico predictions of a p53-mediated control of miR-30a, we
observed that modulation of p53 expression in tumor cell
lines affected miR-30a transcription. Speciﬁcally, ectopic
expression of p53 in TP53-null cells (MDA157) or small
interfering RNA (siRNA)-mediated downregulation of p53
in TP53 wild-type cells (HCT116 and MCF7) associated
with a concordant variation in the expression of both miR-
30a strands (Fig. 2a, b). The ﬁnding that modulation of p53
affected miR-30a expression at the level of primary tran-
script (pri-miRNA; Fig. 2c, d) further supported the notion
of a control of p53 over miR-30a transcription.
To validate this hypothesis we generated a MIR30A
reporter plasmid in which the MIR30A promoter, either wild
type or mutagenized in the two p53 binding sites with the
highest prediction score according to MatInspector (p53BS,
miR30-1 and miR30-2), was cloned upstream of the luci-
ferase gene (Supplementary Figure S2a). Both p53BS single
site (30mut1 and 30mut2) and p53BS dual site mutant
reporters (30mut1/2 with both the predicted p53BS muta-
genized) were generated. Reporter assays indicated that
silencing of p53 (Supplementary Figure S2b) affected the
activity of the MIR30A wild-type reporter, while it had
negligible effects on the reporters in which either one or
both p53BS were destroyed (Fig. 2e comparison black vs
gray matched columns). Moreover, in p53 proﬁcient cells
the luciferase activity was signiﬁcantly reduced in p53BS
mutated reporters compared to the wild-type one (Fig. 2e
comparison between black columns); this difference was
erased after silencing of p53 (Fig. 2e comparison between
gray columns). Overall these data added support to the
notion that miR-30a is a direct transcriptional target of p53.
To ultimately demonstrate that p53 actually sits on the
MIR30A promoter, we performed chromatin immunopreci-
pitation (ChIP) experiments. HCT116 cell lysates were
immunoprecipitated using a p53-speciﬁc antibody and the
regions encompassing the two putative p53BS elements on
the MIR30A promoter (miR30-1 and miR30-2) were
ampliﬁed and quantiﬁed by quantitative PCR (qPCR). Pre-
immune IgG isotype antibodies were used in a mock
immunoprecipitation as a negative control/background sig-
nal; the p53 binding region of the p21 promoter was instead
used as a positive control in PCR reactions. Quantitative
PCR-ChIP conﬁrmed a strong enrichment of the amplicons
encompassing the two p53BS in anti-p53 ChIP compared to
the background (control IgG-ChIP, Fig. 2f). The identiﬁ-
cation of functional binding sites for p53 in the MIR30A
promoter region compellingly demonstrated that miR-30a is
a direct transcriptional target of p53.
miR-30a-5p and miR-30a-3p target ZEB2
Having collected evidence that indicates that p53 directly
controls miR-30a and that p53 inactivation results in miR-
30a downregulation, we then sought to deepen how this
interplay impinged upon the aggressive behavior of TNBC.
To gain insights on the pathways regulated by the p53/miR-
30a axis, we interrogated several in silico prediction tools
(microRNA Data Integration Portal-mirDIP [18]). Compu-
tational analyses identiﬁed several miR-30a targets, among
which include SNAI1, SNAI2 and ZEB2. miR-30a is
known to participate to the control of EMT and cell plas-
ticity/stemness and we conﬁrmed in our cell models the
ability of miR-30a to impinge upon these phenotypes
(Supplementary Figure S3a-d). SNAI1 and SNAI2 have
been previously reported to be regulated by miR-30a
[19–21]. Instead, the ability of miR-30a to target ZEB2 was
a new ﬁnding (Fig. 3a). Intriguingly, both miR-30a strands
were predicted to bind ZEB2 mRNA.
ZEB2 is a transcription factor that plays a crucial role in
the control of cell plasticity and in the orchestration of the
EMT phenomena that occur during embryogenesis [22]. In
analogy with its embryonic function, ZEB2 overexpression
has also been shown to promote EMT in tumors, including
BC [23–25]. Accordingly, ZEB2 sustained the cell motility
of TNBC cell models. In fact, ZEB2 downregulation sig-
niﬁcantly reduced in vitro migration of MDA231,
MDA157, BT549, Hs578T and HCC1395 TNBC cell lines
(Supplementary Figure S4a). Intriguingly, even a reduction
of expression to 50% sufﬁced to impact on cell motility.
Since ZEB2 is also expressed by stromal cells [26], to
speciﬁcally address the involvement of ZEB2 in human
tumor cells we sought to use an in situ approach. Immu-
nohistochemical staining revealed that BCs, particularly the
TNBC/basal-like subset, did express the ZEB2 protein
(Supplementary Figure S4b and c).
Based on these ﬁndings, we explored in vitro whether
miR-30a affected ZEB2 expression. Modulation of miR-30a
expression in BC cell lines inversely correlated with ZEB2
levels: ectopic expression of miR-30a (5p, 3p or both
strands, 5p/3p) resulted in ZEB2 decrease (Fig. 3b and
Supplementary Figure S5a); conversely, anti-miR-mediated
inhibition of miR-30a elicited an increase in ZEB2 levels
(Fig. 3c and Supplementary Figure S5b).
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To ascertain whether ZEB2 was a direct target of miR-
30a-5p and miR-30a-3p, reporter assays were performed
using luciferase reporter constructs carrying the 3’
untranslated region (UTR) sequence of ZEB2, either wild
type (WT) or mutated in the seeds for the two miR-30a
strands (5pMUT, 3pMUT; Fig. 3a). Transfection of miR-
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30a-5p and miR-30a-3p signiﬁcantly inhibited the expres-
sion of the ZEB2 3’UTR wild-type reporter (WT), while it
had no effect on the reporter in which the cognate miR-30a
seeds were mutagenized. The combination of the two
miRNAs showed a quasi-additive effect (5pMUT, 3pMUT;
Fig. 3d and Supplementary Figure S5c).
Overall, these data indicated that miR-30a (5p and 3p
strands) exerts an epigenetic control over ZEB2 mRNA. To
address whether p53 entered into the miR-30a/ZEB2
equation, we ectopically expressed p53 in MDA157. This
cell line was selected because it is p53 null and because of
its negligible expression of miR-200c [27], a possible
confounding factor. In fact, miR-200c is a p53-regulated
miRNA previously reported to be connected to ZEB2 via
reciprocal feedback loop [13, 28]. The augment of miR-30a
induced by ectopic p53 was paralleled by a reduction in
ZEB2 protein levels (Fig. 3e). The existence of a p53
control on ZEB2 via miR-30a was conﬁrmed by the ﬁnding
that anti-miR-mediated interference of miR-30a abrogated
the ability of p53 to affect ZEB2 (Fig. 3e, Supplementary
Figure S6a-d). Taken together, these data indicate that,
beside the previously reported p53-miR-34a-SNAI1 axis
[11, 14], p53 exerts a control over EMT also through the
new route involving miR-30a and ZEB2.
The miR-30a/ZEB2 axis controls TNBC tumor
spreading
To address the biological implication of the p53/miR-30a/
ZEB2 axis in TNBC biology, we ascertained whether miR-
30a actually affected tumor spreading via ZEB2. To this
end, we ectopically expressed miR-30a-5p, miR-30a-3p or
the control miRNA (miRCTR) in MDA231 cells silenced
(siRNA) for ZEB2 or in MDA231 engineered to over-
express ZEB2. Either miR-30a strand inhibited migration of
ZEB2-proﬁcient but not ZEB2-deﬁcient MDA231 cells.
Moreover, ZEB2 overexpression counteracted the inhibi-
tory effect of miR30a-5p and -3p (Fig. 4a and Supple-
mentary Figure S7a-d).
In addition, anti-miR-mediated block of miR-30a affec-
ted cell motility (Fig. 4b). Anti-miR-30a-5p and anti-miR-
30a-3p induced an increase in cell migration of comparable
extent. Noteworthy, both anti-miRNAs elicited ZEB2
upregulation. In contrast, SNAI1, which is reported to be
targeted by miR-30a-5p [20, 21], was upregulated only in
response to the cognate anti-miR-30a-5p (Supplementary
Figure S7e-f). Thus, the modulation in cell motility induced
by anti-miR-30a-3p in this experimental system correlated
only with ZEB2 upregulation. This supports a speciﬁc role
for ZEB2 in the control exerted by miR-30a over cell
motility.
To validate these concepts in vivo, we performed xeno-
transplant experiments using the zebraﬁsh embryo as a
model, whose transparency enables direct visualization of
ﬂuorophore-labeled tumor cells [29, 30]. MDA231 and
MDA157 cells, either silenced for ZEB2 (si1-ZEB2, si2-
ZEB2) or ectopically expressing miR-30a (5p/3p), were
injected in the yolk sac of zebraﬁsh embryos to monitor
tumor cell spreading and in the cardinal vein (duct of
Cuvier) to monitor tail ﬁn invasion [31]. Both
ZEB2 silencing and miR-30a induction resulted in reduced
tumor cell migration (Fig. 4c, d and Supplementary
Figure S8a-b) and halved tail ﬁn invasion (Fig. 4e, f and
Supplementary Figure S8c), indicating a diminished tumor
cell extravasation and distal dissemination.
Overall, these results corroborate the concept that the
miR-30a/ZEB2 axis, which is under the control of p53, is
involved in tumor cell invasion and distal spreading.
The p53/miR-30a/ZEB2 axis impinges upon miR-
200c expression
Finally, in the light of the previously reported negative
control of ZEB1 and ZEB2 over miR-200 [28, 32, 33], we
predicted that miR-30a, by repressing ZEB2, would in turn
affect miR-200c.
In accord with this hypothesis, ectopic expression of miR-
30a (5p/3p) resulted in an upregulation of miR-200c that was
paralleled by a marked ZEB2 downregulation (Fig. 5a, Sup-
plementary Figure S9a and b). Instead, no major and repro-
ducible variations in ZEB1 were observed. These results
support a role for the miR-30a/ZEB2 axis in the control of
miR-200c. Accordingly, silencing of ZEB2, which yielded an
Fig. 2 p53 regulates miR-30a-5p and miR-30a-3p expression. a
Ectopic p53 expression in MDA157 results in an augment of mature
miR-30a-5p and miR-30a-3p levels. The immunoblot on the right
shows p53 expression in MDA157 engineered cells. GAPDH was used
as a loading control. b p53 silencing in HCT116 results in a decrement
of both miR-30a-5p and miR-30a-3p. The extent of p53 silencing is
shown in the right panel. c Ectopic p53 induces an increase of pri-miR-
30a levels in MDA157. d Decrease of pri-miR-30a levels in p53-
depleted HCT116 and MCF7 cells. a–d Gray columns represent p53-
modulated samples; black columns represent control cells. e p53
regulates the MIR30A promoter. Silencing of p53 results in a decre-
ment of the MIR30A promoter activity (30wt). The mutagenesis of the
two p53 binding sites, singularly (30mut1, 30mut2) or in combination
(30mut1/2), abrogates this effect. Results represent the mean value of
three independent experiments ± SD. f p53 binds the miR-30a pro-
moter. Chromatin immunoprecipitation was performed with the DO-1
anti-p53 monoclonal antibody on HCT116 genomic DNA. Isotype-
matched pre-immune mouse IgG was used as a negative control. The
immunoprecipitated chromatin was assayed for the enrichment of the
target MIR30A promoter (miR30-1 and 2, the regions encompassing
the two p53BS) by qPCR. The p53 binding region of the p21 promoter
and an irrelevant genomic region (CTR neg) [59] were used as positive
and negative control, respectively. Data are reported as fold enrich-
ment over control samples (immunoprecipitation with pre-immune
IgG) p values were calculated by two-tailed t-test; *p < 0.05, **p <
0.01.
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augment of miR-200c of similar extent to that induced by
miR-30a, nulliﬁed the ability of this miRNA to induce miR-
200c (Fig. 5a, b, Supplementary Figure S10a and b). The
interplay between the miR-30a/ZEB2 axis and miR-200c in
BC (Fig. 5c) was somehow corroborated by the ﬁnding that
the miR-30a was positively correlated to miR-200c in both
the TCGA and in the in-house TNBC series (Supplementary
Figure S11a-d).
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Discussion
Several lines of evidence demonstrate that inactivation of
p53, the tumor suppressor most frequently involved in
TNBC, affects phenotypes such as EMT and cell plasticity/
stemness that contribute to tumor progression and poor
response to therapies [5, 7, 34–37]. As a transcription fac-
tor, p53 controls the expression of several genes involved in
these phenotypes, including miRNAs [6, 13, 14].
In an attempt to elucidate the mechanisms whereby p53
inactivation contributes to the aggressive behavior of BC
via miRNA, we identiﬁed a novel axis involving p53,
miR-30a and ZEB2. In particular, we found that the
expression of miR-30a (both miR-30a-5p and miR-30a-3p)
was signiﬁcantly reduced in human BC samples carrying
TP53 gene alterations, primarily TNBC, and inversely
correlated with patients’ survival. This phenomenon was
attributable to loss of wild-type p53 activity, rather than to
gain of oncogenic functions [38], as miR-30a down-
regulation was observed not only in tumors with missense
p53 mutations encoding a dysfunctional full-length pro-
tein, but also in tumors carrying alterations resulting in p53
protein loss.
The miR-30 family, which includes ﬁve members
(miR-30a, -30b, -30c, -30d, -30e), has been implicated in
the pathogenesis of different tumor types [39]. Although
they share the same seed sequence, the various members
differ for compensatory sequences which account for their
speciﬁcity and for their diverse and sometime opposite
roles in the regulation of cell proliferation, EMT and
apoptosis [19–21, 40–45]. As about miR-30a, loss of
miR-30a-5p has been reported to favor tumor dissemina-
tion and chemoresistance by promoting EMT [19, 20, 40,
42, 43, 46]. We propose that miR-30a mediates the
control of p53 over these phenotypes, thus contributing to
the aggressive behavior of p53-inactivated breast cancers.
Speciﬁcally, we show that miR-30a is a direct p53 tran-
scriptional target that is downregulated in response to p53
inactivation. Intriguingly, a study conducted on a mela-
noma cell line has recently suggested that p53 may repress
miR-30a by binding the MIR30A promoter to a more
proximal region than the one here described [47].
Although we cannot exclude p53 may exert on miR-30a
different effects depending on the cell context, our data
compellingly demonstrate that there is a positive func-
tional interplay between p53 and miR-30a, both in human
BC and in in vitro cell models. In keeping with our
ﬁndings, miR-30a was among the miRNAs positively
modulated in TP53 wild-type vs TP53-null HCT116 colon
cancer cells [48].
Moreover, we provide evidence that ZEB2 is one
important effector of this p53/miR-30a pathway. We
demonstrate that the reduction in miR-30a expression eli-
cited by p53 inactivation results in an alleviation of miR-
30a-mediated targeting of ZEB2, which correlates with
increased cell plasticity, migration and in vivo dissemina-
tion. Thus, our results of a connection between p53 and
EMT via miR-30a, with ZEB2 as a novel actor in this play,
indicate that the p53/miR-30a/ZEB2 axis contributes to the
poor outcome of TNBC.
Physiologically, the ZEB family of transcription factors
play a pivotal role in neural crest formation and migration
during embryo development, a process involving EMT [49].
In recent years, ZEB factors have gained attention for their
pro-oncogenic functions. As reported for other EMT tran-
scription factors, the expression of ZEB proteins in tumor
cells contributes to the shift from an epithelial towards a
more mesenchymal phenotype and concurrently confers
resistance to DNA damage, apoptosis and premature
senescence [32, 50].
Overexpression of ZEB proteins has been shown to con-
tribute to several cancer types [51, 52] and, in particular, it is
considered an unfavorable factor in BC [25, 53]. ZEB pro-
teins have been previously linked to p53 via miR-200 [13], a
family of p53-regulated miRNAs. In fact, miR-200s establish
with ZEB a double-negative feedback loop [28, 32, 33, 54].
Our results indicate that miR-30a complements this equation.
In fact, miR-30a and miR-200c levels are positively correlated
in human BC and miR-30a-induced downmodulation of
ZEB2 results in miR-200c overexpression.
Overall, this study demonstrates the existence of a
novel axis, p53/miR-30a/ZEB2, that links p53 inactiva-
tion to EMT and BC aggressiveness (Fig. 5c), and adds
support to the notion that the control of p53 over the
various tumoral phenotypes relies on convergent and
integrated circuits, in which miRNAs appear as emerging
and pivotal nodes.
Fig. 3 miR-30a-5p and miR-30a-3p inhibit ZEB2 and mediate the p53
control over ZEB2. a Alignment of ZEB2 3’UTR with miR-30a-5p
and miR-30a-3p (Targetscan). Nucleotides mutagenized to disrupt the
miRNA/mRNA base pairing are underlined. b Immunoblots showing
the modulation of ZEB2 in response to miR-30a (5p, 3p or both)
ectopic expression and c after anti-miR-mediated inhibition of miR-
30a. ZEB2 relative levels, normalized over Tubulin (loading control),
are reported below. d miR-30a targets the 3′UTR of ZEB2: luciferase
activity of the ZEB2 3’UTR reporter, wild-type (WT) or mutated in the
miR-30a-5p and -3p binding sites (5pMUT and 3pMUT), was mea-
sured 48 h post transfection of MDA231 cells with the indicated
miRNAs. miRCTR was set as a reference. CMV-Renilla was used for
normalization. Results represent the mean value ± SD of three
experiments. The asterisks (*) indicate the comparisons of miR-30a vs
miRCTR that are statistically signiﬁcant (p < 0.05). e miR-30a-5p and
miR-30a-3p expression in MDA157 stably transduced with p53
(pLenti-p53+) or pLenti-GFP (pLenti-p53−), in the absence (anti-
miR-30a−) or presence (anti-miR-30a+) of an anti-miRNA targeting
miR-30a. Immunoblots for ZEB2, p53 and Vinculin (loading control)
are shown on the right. Numbers below the blot indicate ZEB2 relative
levels normalized over Vinculin
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Materials and methods
Cell models
The human breast cancer cell lines MDA-MB-157, MDA-
MB-231, MDA-MB-436 (here referred as MDA157,
MDA231 and MDA436), Hs578T, BT549, HCC1395 and
HCT116 colorectal cancer cell lines were obtained from the
ATCC, and HBL100 from Interlab Cell Line Collection-
Genova. All cell lines, periodically authenticated by short
tandem repeat proﬁling and tested mycoplasma-negative,
were cultured as previously described [55].
siRNAs for p53 (HSS110905, HSS186390, HSS186391;
ThermoFisher Scientiﬁc) and non-targeting siRNA (12935-
100; ThermoFisher Scientiﬁc) were transfected using Lipo-
fectamine 3000 (ThermoFisher Scientiﬁc). Ambion Pre-miR
miRNA precursors speciﬁc either for the 5p or the 3p strand
(Life Technologies, ThermoFisher Scientiﬁc), anti-miRNAs
(anti-miR) and relative controls (Life Technologies, Ther-
moFisher Scientiﬁc) were transfected with the siPORT
NeoFX Transfection reagent (ThermoFisher Scientiﬁc)
according to the manufacturer’s instructions. Two ON-
Target-plus siRNAs for ZEB2 (J-006914-22, J-006914-23;
Dharmacon) and a non-targeting siRNA were transfected
using the DharmaFECT reagent 4 (ThermoFisher Scientiﬁc).
Lentiviral delivery, carried out as previously described
[33], was used to generate stable cell models. MDA157
cells stably expressing p53 were generated by using the
pLenti6/V5-p53_wt p53 vector (Addgene plasmid # 22945
[56]). pLenti6GFP was used as a control. MDA231 cells
were engineered to overexpress ZEB2 by transducting the
pLJM-ZEB2 lentiviral vector or pLJM1-EGFP (Addgene #
19319 [57]) as a control. To generate pLJM-ZEB2, ZEB2
coding sequence was ampliﬁed from TOPO-Blunt-ZEB2
vector (HsCD000347714; Harvard Medical School, Boston)
with primers containing AgeI and BstBI sites and cloned
into pLJM1-EGFP.
ZEB2-silenced (sh1-ZEB2, sh2-ZEB2 or sh5-ZEB2) and
control cells (shGFP) (MDA231, MDA157, HBL100,
Hs578T, BT549 and HCC1395) were generated by using
lentiviral plasmids obtained from a modiﬁed version of
pRSI9 DECIPHER vector (Cellecta) in which an AgeI site
was introduced by mutagenesis. Individual sequences for
shZEB2 and shGFP (Supplementary Table S1) were cloned
in the AgeI and EcoRI sites.
The MIR200C promoter is notoriously constitutively
methylated in the TNBC cell lines and several cell divisions
are needed to achieve appreciable reactivation by deme-
thylating agents [33, 58]. Thus, stable cell models were
needed to address the hypothesis of a miR-30a/ZEB2-
mediated activation of miR-200c. To this end, MDA231,
MDA157 and HBL100 were engineered to express miR-30a
(5p/3p) or silenced for ZEB2 via lentiviral delivery. Con-
stitutive miR-30a (5p/3p) overexpression was achieved by
lentiviral infection with pLenti6-miR-30a-(5p/3p) or pLen-
ti6GFP vectors. MIR30A (miR-30a (5p/3p)) genomic
region, ampliﬁed from MCF7 genomic DNA with primers
containing XhoI and NotI sites (Supplementary Table S1),
was initially cloned in pLNCX2-vector. The MIR30A
fragment was then cleaved with BglII and ClaI restriction
enzymes and inserted into BamHI and BstBI restriction sites
of pLenti6GFP.
TCGA dataset
A dataset of 249 BC samples comprising clin-
icopathological information, miRNA-seq data and TP53
mutational status was retrieved (on December 2014) from
TCGA portal (http://tcga-data.nci.nih.gov/tcga/
ﬁndArchives.htm [16]). The set included 204 BC hormo-
nal receptor positive, 27 TNBC and 13 expressing HER2
but lacking hormonal receptors (5 cases were unknown).
Besides, 163 BCs presented wild-type TP53 and 82 carried
TP53 mutations (4 were unknown). miRNAs data of paired
tumor and normal tissues were collected for 12 cases.
miRNA-seq data and clinicopathological records of further
63 TNBC were downloaded from TCGA data portal. Col-
lected miRNA-seq data (level 3) included the calculated
Fig. 4 miR-30a (5p/3p) overexpression results in a reduced BC cell
migration in vitro and in a zebraﬁsh xeno-transplantation model. a In
vitro cell migration assay of MDA231 engineered to ectopically
express miR-30a-5p, miR-30a-3p or control miRNA (miRCTR) in a
ZEB2-proﬁcient (siCTR) or ZEB2-deﬁcient (si1-ZEB2 and si2-ZEB2)
context (left panel). The right panel shows the migration capacity of
MDA231 engineered to stably overexpress ZEB2 or GFP, used as a
negative control. b In vitro cell migration assay of MDA231 trans-
fected with anti-miR-30a-5p (A-miR-30a-5p), anti-miR-30a-5p (A-
miR-30a-5p) or control anti-miRNA (A-CTR). The percentage of
transmigrated cells was measured at 7 h post seeding. Data represent
the mean of three independent experiments; *p < 0.05. c Scatter plot
representing cell dissemination in zebraﬁsh embryos of mCHERRY
MDA231 transiently silenced for ZEB2 (si1-ZEB2 and si2-ZEB2) or
engineered to stably express miR-30a (5p/3p). Cells transfected with
an empty vector were used as a control (ctr). Cells were implanted in
the yolk sac of 2-day-old embryos (ﬂi1:EGFP strain). Embryos were
automatically imaged at 6 dpi. Dots represent single cells; colors
identify each microinjected embryo; x-axis indicates the migration
from the injection point (0,0) toward the head (positive values) or the
tail (negative values); n indicates the number of embryos analyzed. d
Spreading distance of MDA231 and MDA157 calculated from data
represented in (c) and in Supplementary Figure S8b, respectively; *p <
0.05. e Representative images of zebraﬁshes injected with
MDA231 cells at 6 dpi. Cells were injected into the blood circulation
(duct of Cuvier) of 2-day-old zebraﬁsh embryos. Scale bar= 100 µm. f
Percentages of embryos that show caudal micrometastatic colonization
after injection with MDA231 or MDA157 cells engineered with
control vector (ctr), miR-30a (5p/3p) or silenced for ZEB2 (si1-ZEB2
and si2-ZEB2). The percentage of ctr embryos showing metastasis was
arbitrarily set to 100. Data are shown at 1, 4 and 6 dpi. Figures
represent the results of two independent experiments
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expression for all reads aligned to a speciﬁc miRNA
reported as RPM (reads per million miRNA mapped).
Comparisons were performed on LOG2 of RPM values.
Analyses reported in Table 1 were performed by using data
from mirnas.quantiﬁcation ﬁles; in the analyses of miR-30a
isoforms the isoform.quantiﬁcation ﬁles were used.
Fig. 5 The p53/miR-30a/ZEB2
axis impinges upon miR-200c. a
miR-200c levels in MDA231,
MDA157 and HBL100 cell lines
engineered to express miR-30a
(5p/3p) or silenced for ZEB2
(sh1-ZEB2; sh2-ZEB2). Control
vectors (pLenti6GFP and
shGFP) yielded similar values
and are here represented once as
ctr. miR-200c levels in HBL100
ctr were set to 1. b miR-200c
levels in MDA231 proﬁcient
(shGFP) or deﬁcient (sh1-ZEB2,
sh2-ZEB2) for ZEB2
expression, in the absence (ctr,
pLenti6GFP) or presence (miR-
30a-5p/3p) of ectopic miR-30a;
*p < 0.05. c A unifying model of
the new p53/miR-30a/ZEB2 axis
(highlighted in bold) involved in
TNBC
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Patients and samples
Formalin-ﬁxed, parafﬁn-embedded (FFPE) specimens of 59
TNBCs were retrospectively collected at the CRO Aviano
National Cancer Institute biobank (2000–2010). Cases were
selected based on the following criteria: naive for che-
motherapy and radiotherapy, tumor cellularity greater than
70%, suitability of the material for molecular analyses.
Informed consent was obtained and use of patient samples
was approved by the Institutional Review Board. Clin-
icopathological and follow-up data were retrieved from
clinical records (Table 2).
RNA extraction and qRT-PCR
Total RNA was isolated from FFPE tumors samples using
the Recover All Total Nucleic Acid Isolation Kit (Ther-
moFisher Scientiﬁc). The miRNeasy Mini Kit (Qiagen) was
used to isolate total RNA from cell lines. Complementary
DNA was generated by using SuperScriptIII-Reverse
Transcriptase (Applied Biosystems, ThermoFisher Scien-
tiﬁc) for pri-miRNA detection and by TaqMan MicroRNA
Reverse Transcription Kit (Life Technologies, Thermo-
Fisher Scientiﬁc) for miRNA analyses. Pri-miR-30a, miR-
NAs (miR-30a-5p, miR-30a-3p, miR-200c) and RNU48
and RNU6B (reference genes) were then ampliﬁed by
quantitative reverse transcription-PCR (qRT-PCR) using
TaqMan-speciﬁc kits (Life Technologies, ThermoFisher
Scientiﬁc). Relative expression levels were normalized to
controls (geometric mean of the reference genes) by using
the comparative Ct (ΔΔCt) method and the Bio-Rad CFX
manager software. All experiments were done in triplicate
and conﬁrmed in at least three independent experiments.
Dual-Luciferase reporter assay
The miR-30a promoter region was ampliﬁed from genomic
DNA extracted from MCF7 cells and cloned into the pGL3
basic Luciferase vector (Promega). The 3’UTR of ZEB2
was ampliﬁed from genomic DNA extracted from MDA231
and cloned in pMIR-REPORTTM Luciferase vector (Ther-
moFisher Scientiﬁc). The p53 binding sites identiﬁed on the
miR-30a promoter by the MatInspector software (Geno-
matix Software GmbH, Munich, Germany) and the miR-
30a-5p and miR-30a-3p binding sites on the 3’UTR of
ZEB2 were modiﬁed by site-direct mutagenesis (Quik-
ChangeTM Site-Directed Mutagenesis Kit, Stratagene). The
primers used for ampliﬁcation and mutagenesis are reported
in Supplementary Table S1.
Reporter plasmids were transiently transfected in the
indicated cell lines using the Lipofectamine 3000 reagent
(ThermoFisher Scientiﬁc); pCMV-Renilla or PGK-Renilla
were used for normalization. siRNA and pre-miRNA were
transfected at 25 nM ﬁnal concentration. Reporter assays
were performed 48 h after transfection using the Dual-
luciferase assay system (Promega). Transfection efﬁciency
was normalized by calculating the Luciferase/Renilla
activity ratio. All experiments were done in triplicate and
data conﬁrmed in at least three independent experiments.
Western blot analyses
Protein extraction and western blot were performed as
previously described [55]. Detailed description of the used
antibodies is reported in Supplementary Table S2. Immu-
noreactivity was detected with anti-mouse and anti-rabbit
secondary antibodies horseradish peroxidase labeled (Per-
kinElmer) using Western Lightning™ Chemiluminescence
Reagent Plus (PerkinElmer). Images were captured and
analyzed using the Chemidoc XRS+ system (Bio-Rad).
Expression levels were quantiﬁed using the ImageLab
imaging software (Bio-Rad). Results were conﬁrmed in at
least three independent experiments.
Chromatin immunoprecipitation
Chromatin crosslinking was performed according to the
protocol developed by P.J. Farnham (available online at:
http://farnham.genomecenter.ucdavis.edu/pdf/FarnhamLa
bChIP%20Protocol.pdf).
For ChIP, 4 µg of DO-1 anti-p53 monoclonal antibody or
isotype-matched pre-immune mouse IgG, as a negative
control, were used. Quantitative real-time PCRs with the
EvaGreen dye technology (Bio-Rad) was used to quantify
the DNA in ChIP samples. Analysis of ChIP data was
carried out using the fold enrichment method normalized to
mock (IgG) control for each sample (ThermoFisher Scien-
tiﬁc, https://tools.thermoﬁsher.com/content/sfs/brochures/
Step-by-Step-Guide-to-Successful-ChIP-Assays.pdf).
Details about oligonucleotides and antibodies are reported
in Supplementary Table S1 and S2, respectively. The oli-
gonucleotides used for positive and negative controls were
as previously described [59]. The results were conﬁrmed in
two independent experiments.
Migration assays
Migration assays were performed on several cell models
modulated for ZEB2 and/or miR-30a expression, namely:
MDA231, MDA157, BT549, Hs578T and HCC1395 stably
silenced for ZEB2 via lentiviral delivery; ZEB2-silenced/
miR-30a overexpressing MDA231 cell models, generated
by ﬁrst transfecting ZEB2-speciﬁc siRNAs or non-targeting
siRNA (ThermoFisher Scientiﬁc, 25 nM) and then (24 h
later) by further transfecting pre-miR-30a-5p, pre-miR-30a-3p
or pre-miR control (Ambion, 5 nM); MDA231 cells
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engineered to stably express ZEB2 or control, transfected with
pre-miR-30a-5p, pre-miR-30a-3p or pre-miRNA control
(Ambion, 5 nM); MDA231 cells transfected with anti-
miRNAs and relative control (ThermoFisher Scientiﬁc,
10 nM). At 48 h post transfection, cells were collected for
subsequent analyses.
Migration assays were performed as described in Spes-
sotto et al. [60]. Brieﬂy, cells were trypsinized, collected
and ﬂuorescently labeled with Fast DiI dye solution
(Molecular Probes, Inc.) for 10 min at 37 °C in 5% CO2.
Cells were then washed in serum-free medium and seeded
(105 cells/insert) in serum-free medium on the top side of
Fluoroblok inserts (Corning). Medium containing 10% of
fetal bovine serum was used as chemoattractant in the lower
chamber (bottom side). Fluorescence intensity at 576 nm of
top (nonmigrated cells) and bottom (transmigrated cells)
side of the well was measured at the indicated time points
(tx, 7 or 24 h) using a microplate reader (Inﬁnite
M1000PRO, TECAN). The percentage of transmigrated
cells was determined as follows: 100×(FBtx−FBt0)/FTt0
where FBtx is the ﬂuorescence intensity of bottom side at
the indicated time point; FBt0 is the ﬂuorescence intensity of
bottom side at the time zero; FTt0 is ﬂuorescence intensity
of top side at the time zero. All experiments were performed
in triplicate and data conﬁrmed in at least three independent
experiments.
Zebraﬁsh in vivo experiments
To address the role of the mir-30a/ZEB2 axis in vivo,
experiments were performed using the zebraﬁsh embryo
model. We choose this model because, beside meeting the
3R recommendations of using animals with a reduced ner-
vous system development, its transparency allows an
effective and real-time assessment of tumor cell growth and
migration.
The transgenic zebraﬁsh line Tg (ﬂi1:EGFP), expressing
enhanced green ﬂuorescent protein (EGFP) in endothelial
cells in wild-type background, was used for in vivo evalua-
tion of tumor cell dissemination and micrometastatization.
Zebraﬁsh and embryos were raised, staged and maintained
according to standard procedures (http://ZFIN.org) in com-
pliance with the local animal welfare regulations.
BC cells, engineered as speciﬁed in the text and made
ﬂuorescent following infection with the mCHERRY lenti-
viral vector (pCMV-mCherry-bc-puro-Kl201), were injec-
ted in the yolk sac and analyzed as previously described
[29]. Tumor dissemination was measured as “spreading
distance per object” representing the mean cell migration
for each embryo.
To investigate the ability of engineered cells to extra-
vasate and form distal metastasis, mCHERRY-positive BC
cells were injected into the duct of Cuvier of 2-day-old ﬂi1:
EGFP embryos. The fraction of embryos exhibiting
micrometastastatic colonization of the caudal ﬁn (>10 cells)
was calculated at 1, 4 and 6 dpi (days post injection), as
previously described [31]. Data are representative of two
independent experiments with at least 24 embryos per
group. All experiments were performed twice.
Statistical analyses
For miRNA expression analysis tumor samples were cate-
gorized according to the median expression value into
“low” (expression levels<median) and “high” (expression
levels≥median). The Mann–Whitney–Wilcoxon test and
Fisher’s exact test were used to assess associations between
miRNA expression and selected prognostic factors (age at
diagnosis, tumor size, lymph nodes status, metastasis, TNM
(tumor, node, metastasis) stage, tumor grade and treat-
ments). Survival analyses were conducted considering the
time from diagnosis to the date of the event (death, relapse
or last follow-up). Overall and disease-free survivals were
estimated using the Kaplan–Meier method and differences
between curves were evaluated using the log-rank test.
Differences in miRNA expression levels between groups
were assessed by using Mann–Whitney rank sum test for
TCGA dataset (values not normally distributed) and by
t-test for the in-house series (values normally distributed
and equal variance between groups). Statistical analyses for
in vitro experiments were performed using two-tailed t-test.
Correlation between miRNA levels was evaluated by cal-
culating Spearman’s correlation coefﬁcient (r). Statistical
analyses were performed with SAS 9.4 (SAS Institute Inc.)
and SigmaPlot (Systat Software Inc.).
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